ACE gene insertion/deletion polymorphism is associated with glioblastoma in an Iranian population: a case-control study

ACE gene insertion/deletion polymorphism is associated with glioblastoma in an Iranian population: a case-control study

Автор: Moqadami A., Agah E.M., Khalaj-kondori M.

Журнал: Сибирский онкологический журнал @siboncoj

Рубрика: Лабораторные и экспериментальные исследования

Статья в выпуске: 2 т.22, 2023 года.

Бесплатный доступ

Background. The insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme (ACE) gene has recently been reported to be associated with the pathogenesis and development of human cancers. This study aimed to assess the potential association between ACE (I/D) polymorphism and glioblastoma in an Iranian population. Material and Methods. This case-control study was conducted on 80 patients with glioblastoma and 80 healthy blood donors as controls. Gap-polymerase chain reaction (Gap-PCR) was used to determine the ACE (I/D) genotypes. PCR products were separated and measured by electrophoresis on a 2 % agarose gel. Results. Analysis of demographic data showed a significant difference in the family history of cancer between the case and control groups (p=0.03). The distribution of ACE gene variants including II, ID, and DD genotypes was also calculated, and significant differences were seen in the DD genotype (p=0.03) and D allele (p=0.04) between the glioblastoma cases and controls. Conclusion. ACE gene polymorphism was associated with glioblastoma in the study population. Further studies are needed to approve this finding.

Еще

Angiotensin-converting enzyme, ace i/d polymorphism, glioblastoma, gap-pcr

Короткий адрес: https://sciup.org/140300169

IDR: 140300169   |   DOI: 10.21294/1814-4861-2023-22-2-85-92

Список литературы ACE gene insertion/deletion polymorphism is associated with glioblastoma in an Iranian population: a case-control study

  • Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., Burger P.C., Jouvet A., ScheithauerB.W., KleihuesP. The 2007 WHO classification of tumours of the central nervous system. Acta Neu-ropathol. 2007; 114(2): 97-109. doi: 10.1007/s00401-007-0243-4. Erratum in: Acta Neuropathol. 2007; 114(5): 547.
  • Tan A.C., Ashley D.M., López G.Y., Malinzak M, Friedman H.S., Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4): 299-312. doi: 10.3322/caac.21613.
  • RockK., McArdle O., Forde P., DunneM., FitzpatrickD., O'Neill B., Faul C. A clinical review of treatment outcomes in glioblastoma multiforme--the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol. 2012; 85(1017): 729-33. doi: 10.1259/bjr/83796755.
  • Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007; 170(5): 1445-53. doi: 10.2353/ajpath.2007.070011.
  • Ostrom Q.T., Patil N., Cioffi G., Waite K., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020; 22(12 Suppl 2): 1-96. doi: 10.1093/neuonc/noaa200. Erratum in: Neuro Oncol. 2022; 24(7): 1214.
  • Thakkar J.P., Dolecek T.A., Horbinski C., Ostrom Q.T., Lightner D.D., Barnholtz-Sloan J.S., Villano J.L. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev. 2014; 23(10): 1985-96. doi: 10.1158/1055-9965.EPI-14-0275.
  • Ohka F., Natsume A., Wakabayashi T. Current trends in targeted therapies for glioblastoma multiforme. Neurol Res Int. 2012. doi: 10.1155/2012/878425.
  • O'Rawe M., Kilmister E.J., Mantamadiotis T., Kaye A.H., Tan S.T., Wickremesekera A.C. The rennin-angiotensin system in the tumor microenvironment of glioblastoma. Cancers. 2021; 13(16): 4004. doi: 10.3390/cancers13164004.
  • Nakagawa P., Gomez J., Grobe J.L., Sigmund C.D. The renin-angiotensin system in the central nervous system and its role in blood pressure regulation. Current hypertension reports. 2020; 22(1): 1-10.
  • Jackson L., Eldahshan W., Fagan S.C., Ergul A. Within the Brain: The Renin Angiotensin System. Int J Mol Sci. 2018; 19(3): 876. doi: 10.3390/ijms19030876.
  • Labandeira-Garcia J.L., Rodriguez-Perez A.I., Garrido-Gil P., Rodriguez-Pallares J., Lanciego J.L., Guerra M.J. Brain Renin-Angiotensin System and Microglial Polarization: Implications for Aging and Neurodegeneration. Front Aging Neurosci. 2017; 9: 129. doi: 10.3389/fnagi.2017.00129.
  • Xu Q., Jensen D.D., Peng H., Feng Y. The critical role of the central nervous system (pro)renin receptor in regulating systemic blood pressure. Pharmacol Ther. 2016; 164: 126-34. doi: 10.1016/j.pharmthera.2016.04.006.
  • Riquier-Brison A.D.M., Sipos A., Prokai A., Vargas S.L., Toma L., Meer E.J., Villanueva K.G., Chen J.C.M., Gyarmati G., Yih C., TangE., Nadim B., PendekantiS., Garrelds I.M., Nguyen G., DanserA.H.J., Peti-Peterdi J. The macula densa prorenin receptor is essential in renin release and blood p ressure control. Am J Physiol Renal Physiol. 2018; 315(3): 521-34. doi: 10.1152/ ajprenal.00029.2018.
  • Bodiga V.L., Bodiga S. Renin angiotensin system in cognitive function and dementia. Asian J Neurosci. 2013. Article ID 102602. doi: 10.1155/2013/102602.
  • HammingI., Timens W., BulthuisM.L., LelyA.T., Navis G., van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004; 203(2): 631-7. doi: 10.1002/ path.1570.
  • Cui C., Xu P., Li G., Qiao Y., Han W., Geng ^ C., Liao D., Yang M., Chen D., Jiang P. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role ofrenin-angiotensin system. Redox Biol. 2019; 26. doi: 10.1016/j. redox.2019.101295.
  • Balyasnikova I.V., Metzger R., Sun Z.L., Berestetskaya Y. V., Albrecht R.F., Danilov S.M. Development and characterization of rat monoclonal antibodies to denatured mouse angiotensin-converting enzyme. Tissue Antigens. 2005; 65(3): 240-51. doi: 10.1111/j.1399-0039.2005.00364.x.
  • Nakagawa P., Sigmund C.D. How Is the Brain Renin-Angiotensin System Regulated? Hypertension. 2017; 70(1): 10-8. doi: 10.1161/HYPERTENSI0NAHA.117.08550.
  • Ziaja M., Urbanek K.A., Kowalska K., Piastowska-Ciesielska A.W. Angiotensin II and Angiotensin Receptors 1 and 2-Multifunctional System in Cells Biology, What Do We Know? Cells. 2021; 10(2): 381. doi: 10.3390/cells10020381.
  • Bradshaw A.R., Wickremesekera A.C., Brasch H.D., Chibnall A.M., Davis P.F., Tan S.T., Itinteang T. Glioblastoma Multiforme Cancer Stem Cells Express Components of the Renin-Angiotensin System. Front Surg. 2016; 3: 51. doi: 10.3389/ fsurg.2016.00051.
  • Kouchi M., Shibayama Y., Ogawa D., Miyake K., Nishi-yama A., Tamiya T. (Pro)renin receptor is crucial for glioma development via the Wnt/ß-catenin signaling pathway. J Neurosurg. 2017; 127(4): 819-28. doi: 10.3171/2016.9.JNS16431.
  • Hicks B.M., Filion K.B., Yin H., Sakr L., Udell J.A., Azoulay L. Angiotensin converting enzyme inhibitors and risk of lung cancer: population based cohort study. BMJ. 2018; 363. doi: 10.1136/bmj.k4209.
  • Moghimi M., Kargar S., Jafari M.A., Ahrar H., Jarah-zadeh M.H., Neamatzadeh H., Sadeghizadeh-Yazdi J. Angi-otensin Converting Enzyme Insertion/Deletion Polymorphism is Associated with Breast Cancer Risk: A Meta-Analysis. Asian Pac J Cancer Prev. 2018; 19(11): 3225-31. doi: 10.31557/ APJCP2018 19 11 3225
  • 24.' Wang Z.Y., Li H.Y., Jiang Z.P., Zhou T.B. Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and prostate cancer susceptibility. J Cancer Res Ther. 2018; 14(S): 375-80. doi: 10.4103/0973-1482.171366.
  • Pabalan N., Jarjanazi H., OzcelikH. Associations of the Insertion/Deletion Polymorphism in the ACE Gene and Risk of Gastric Cancer: A Meta-Analysis. J Gastrointest Cancer. 2015; 46(4): 370-9. doi: 10.1007/s12029-015-9754-8.
  • Röcken C., Lendeckel U., Dierkes J., Westphal S., Carl-McGrath S., Peters B., Krüger S., Malfertheiner P., Roessner A., EbertM.P. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/ deletion polymorphism. Clin Cancer Res. 2005; 11(7): 2526-30. doi: 10.1158/1078-0432.CCR-04-1922.
  • VairaktarisE., Yapijakis C., Tsigris C., Vassiliou S., Derka S., Nkenke E., Spyridonidou S., Vylliotis A., Vorris E., Ragos V, Neukam F.W., Patsouris E. Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Acta Oncol. 2007; 46(8): 1097-102. doi: 10.1080/02841860701373579.
  • Kitsios G., Zintzaras E. ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet. 2009; 10: 50. doi: 10.1186/1471-2350-10-50.
  • Haiman C.A., Henderson S.O., Bretsky P., Kolonel L.N., Henderson B.E. Genetic variation in angiotensin I-converting enzyme (ACE) and breast cancer risk: the multiethnic cohort. Cancer Res. 2003; 63(20): 6984-7.
  • RigatB., HubertC., Alhenc-GelasF., Cambien F., CorvolP., SoubrierF. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4): 1343-6. doi: 10.1172/JCI114844.
  • Jeunemaitre X. Genetics of the human renin angiotensin system. J Mol Med (Berl). 2008; 86(6): 637-41. doi: 10.1007/ s00109-008-0344-0.
  • Suehiro T., Morita T., InoueM., Kumon Y., Ikeda Y., Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum Genet. 2004; 115(2): 91-6. doi: 10.1007/s00439-004-1136-4.
  • Holland E.C. Glioblastoma multiforme: the terminator. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97(12): 6242-4. doi: 10.1073/ pnas.97.12.6242.
  • Maher E.A., Furnari F.B., Bachoo R.M., Rowitch D.H., Louis D.N., Cavenee W.K., DePinho R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15(11): 1311-33. doi: 10.1101/gad.891601.
  • Schwartzbaum J.A., Fisher J.L., Aldape K.D., WrenschM. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006; 2(9): 494-503. doi: 10.1038/ncpneuro0289.
  • Agnihotri S., Burrell K.E., Wolf A., Jalali S., Hawkins C., Rutka J.T., Zadeh G. Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. Arch Immunol Ther Exp (Warsz). 2013; 61(1): 25-41. doi: 10.1007/s00005-012-0203-0.
  • Ostrom Q.T., GittlemanH., TruittG., BosciaA., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. Neuro Oncol. 2018; 20(s4):1-86. doi: 10.1093/neuonc/noy131. Erratum in: Neuro Oncol. 2018.
  • Lian M., Jiang H., Wang H., Guo S. Angiotensin-converting enzyme insertion/deletion gene polymorphisms is associated with risk of glioma in a Chinese population. J Renin Angiotensin Aldosterone Syst. 2015; 16(2): 443-7. doi: 10.1177/1470320313495910.
  • Pandith A.A., Qasim I., Zahoor W., Shah P., BhatA.R. ACE I/D sequence variants but not MTHFR C677T, is strongly linked to malignant glioma risk and its variant DD genotype may act as a promising predictive biomarker for overall survival of glioma patients. Gene. 2018; 639: 62-8. doi: 10.1016/j.gene.2017.10.013.
  • Benenemissi I.H., Sifi K., Sahli L.K., Semmam O., Abadi N., Satta D. Angiotensin-converting enzyme insertion/ deletion gene polymorphisms and the risk of glioma in an Algerian population. Pan Afr Med J. 2019; 32: 197. doi: 10.11604/ pamj.2019.32.197.15129.
  • Sun M., Fang Y., Ma S., Gao X., Sun Y. The genetic polymorphisms of angiotensin converting enzyme insertion/deletion and glioma susceptibility: A meta-analysis. J Renin Angiotensin Aldosterone Syst. 2020; 21(4). doi: 10.1177/1470320320963939.
Еще
Статья научная
SciUp 2024 © 2024 ©